Multi-omics-led Tech Consulting in the Age of Generative Biology: Modernizing Labs for Building Foundation-scale Models

Looking back a decade ago, it’s amusing how we were all fascinated by J.A.R.V.I.S. in the movie Iron Man, an NLP-based interface developed by the protagonist Tony Stark. It could retrieve real-time medical images and suggest the best treatment; eventually evolving into a super-intelligent model that handled most of the Iron Legion’s businesses. Only today, we are one step away from achieving this reality!

Health and life sciences research, as we know them, are no longer operating in the conventional way. Although the basic principles remain unchanged, the outlook, methods, and outcomes have evolved, driven by the convergence of artificial intelligence (AI), high-throughput genomics, multi-omics, and precision medicine engineering. Massive, foundation-scale AI models are changing the way healthcare and life science leaders can accelerate scientific outcomes at an unprecedented rate. With a burgeoning global AI-led genomics market projected to grow at a CAGR of over 11.5% from 2025 to 2034, organizations and companies must recalibrate their approaches towards diagnostics, drug discovery, and value-based care.

How Far Have We Made It

Currently, large-scale AI models are trained on vast and diverse biological datasets, including genomics, proteomics, and metabolomics. They can understand and even generate novel biological designs, traversing beyond simple analysis, enabling scientists to carry out the following:

Design novel proteins and therapies

Generative models can create proteins engineered for specific tasks, such as targeting new disease variants or breaking down environmental pollutants. The 2024 Nobel Prize in Chemistry is one such example where David Baker, Demis Hassabis, and John Jumper were honored for unraveling AI-driven protein structure prediction and de novo design (Rosetta, AlphaFold)—spotlighting how generative models can craft entirely new protein folds for vaccines, enzymes, and therapeutics.

Propose innovative biochemical pathways

Through such models, researchers and health personnel can gain deeper insights into the unique biochemical reaction pathways to synthesize desired molecules, significantly enhancing synthetic biology. These could include cost-effective, greener, zero side-effect drug development routes using AI-led analysis to optimize temperature, toxicity, and prices, or accelerating the discovery of biosensors and feedback loops to self‑regulate heterologous pathways in microbial cell factories, via AI/ML-driven metabolic control circuit design.

Accelerate drug discovery

By sifting through vast datasets, AI can identify promising drug targets with unparalleled speed, potentially shortening the drug development cycle from 10-15 years to under 5. In fact, the first drug candidates developed using AI/ML are now entering Phase 2 clinical trials. Wired reports that Recursion has advanced eight AI-designed candidates—including a MALT1 inhibitor—from thousands of in silico hits into early-phase trials, illustrating a paradigm shift from traditional high-throughput screening to model-driven lead selection.

Together, these advancements underscore a transformative shift—where AI isn’t just crunching data, but architecting biology’s next breakthroughs. Recently, at the World Orphan Drug Conference (WODC) USA 2025, experts showcased GenAI models that sift through unstructured multi-omics and clinical data—ranging from whole-genome sequences and proteomics to voice and image biomarkers—to flag potential rare disease cases well before traditional pipelines, thereby preventing prolonged diagnostic delays. By mapping patient-specific molecular signatures against drug response databases, these models can then match individuals with the most suitable therapies, forging a faster path to personalized treatment. Harnessing such powerful, autonomous capabilities, however, calls for stringent regulatory oversight and transparent auditability.

The Imperative for a Modern Tech Strategy

For CROs and diagnostic labs to harness the power of foundation-scale models, a forward-thinking tech strategy is not just a competitive advantage; it's a necessity. Healthcare and life sciences leaders must address the following key pillars to maximize advantage:

High-performance computing infrastructure

Training and running massive AI models require significant computational power, such as NVIDIA’s specialized platform that supports these intensive workloads. Organizations must invest in or have access to robust cloud engineering and on-premise high-performance computing (HPC) environments.

Data engineering and governance

The adage "garbage in, garbage out" has never been more relevant. Foundation models are only as good as the data on which they are trained. A sound data engineering and governance strategy is crucial for ensuring data quality, integrity, and security. This includes FAIR (Findable, Accessible, Interoperable, and Reusable) data principles to maximize the value of data assets.

Automation and APIs

How to effectively streamline workflows and integrate AI models into existing laboratory processes without compromising on output quality and compliance?

This is where automation and well-defined APIs step in, enabling seamless data flow from instruments to AI models and back to researchers, thereby accelerating the research and development lifecycle.

Bespoke application development

Off-the-shelf solutions may not always meet the unique needs of a specific lab or research question. The ability to develop bespoke applications that leverage AI models can provide a significant competitive advantage.

Although the above measures can significantly contribute to elevating the overall quality of products, service, care, and customer support, the entire lifecycle is compromised without robust governance as the underlying foundation of responsible AI adoption.

Governance: The Cornerstone of Responsible AI Adoption

The power of generative AI in life sciences comes with significant responsibilities. A comprehensive governance framework is essential to ensure ethical, safe, and compliant adoption of these technologies. Key considerations include:

Establishing an AI governance council

A cross-functional team with representation from IT, legal, compliance, and scientific departments can devise the AI strategy, defining ethical guidelines, and overseeing the responsible implementation of AI models.

A responsible AI framework

An ideal framework is one that addresses potential risks, such as bias in algorithms, data privacy (especially with sensitive patient data), and the "black box" nature of some AI models. Cross-collaboration among researchers, clinicians, and regulatory bodies can help build the transparency and explainability that are critical to bolstering the value chain.

Regulatory compliance

Matching pace with the constantly evolving regulatory landscape can be a struggle for many organizations – but it is not unachievable. Auditability by design, where documentation and lineage of models are meticulously tracked, is becoming a standard requirement. With the right combination of specific skills, technology, and contextual insights, organizations must stay informed about regulations from bodies such as the FDA and ensure that their AI models and workflows are compliant.

Human-in-the-loop oversight

While AI can automate and accelerate many tasks, human oversight remains crucial, especially in critical decision-making processes. A "human-in-the-loop" approach ensures that AI is used as a tool to augment human expertise, not replace it.

Seizing the Opportunity

The growing market, along with evolving patient demands and stakeholder expectations for a more cohesive care value chain, highlights the massive potential for growth and innovation in technology consulting for genomics. However, building powerful generative biology models requires a robust tech strategy and a clear governance framework. As a leader in AI/ML and data science for scientific advancement, ClairLabs is at the forefront of this transformation, offering the right expertise needed to navigate this complex landscape. By partnering with us and leveraging our deep domain knowledge of the industrial landscape, health care entities, centers, CROs, and diagnostic labs can confidently navigate the complexities of responsible AI adoption. Together, we can drive scientific progress, cut research and development costs, expedite the development of life-saving therapies, and shape the future of healthcare.

Watch this space for more interesting opinions and insights!